Direct Oral Anticoagulant Use in Chronic Kidney Disease and Dialysis Patients With Venous Thromboembolism: A Systematic Review of Thrombosis and Bleeding Outcomes.
Catherine Y S CheungJash ParikhAshley FarrellMelissa LefebvreClaudia Summa-SorginiMarisa BattistellaPublished in: The Annals of pharmacotherapy (2020)
Apixaban may be used cautiously as an alternative in acute VTE treatment in severe CKD patients. Insufficient evidence is available to suggest the use of dabigatran and rivaroxaban in this patient population. The benefit of using DOACs in this population for VTE treatment should be weighed against the potential bleeding risk in patients with CKD.
Keyphrases
- venous thromboembolism
- direct oral anticoagulants
- atrial fibrillation
- chronic kidney disease
- end stage renal disease
- ejection fraction
- peritoneal dialysis
- newly diagnosed
- early onset
- case report
- risk assessment
- adipose tissue
- climate change
- drug induced
- metabolic syndrome
- hepatitis b virus
- intensive care unit
- mechanical ventilation
- extracorporeal membrane oxygenation